S Köhler
Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Köhler S, Tschopp O, Sze L, Neidert M, Bernays R, Spanaus K, Wiesli P, Schmid C. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?. Gen Comp Endocrinol 2013; 188:282-7.
04.05.2013Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
04.05.2013Gen Comp Endocrinol 2013; 188:282-7
Köhler S, Tschopp O, Sze Lisa, Neidert M, Bernays R-L, Spanaus K-S, Wiesli P, Schmid C
[Tiredness, hyperpigmentation, weight loss, nausea and vomiting. Polyglandular autoimmune syndrome (PAS) type 2]
Locher R, Köhler S, Schwanda S, Schmid C. [Tiredness, hyperpigmentation, weight loss, nausea and vomiting. Polyglandular autoimmune syndrome (PAS) type 2]. Praxis (Bern 1994) 2010; 99:1223-8.
06.10.2010[Tiredness, hyperpigmentation, weight loss, nausea and vomiting. Polyglandular autoimmune syndrome (PAS) type 2]
06.10.2010Praxis (Bern 1994) 2010; 99:1223-8
Locher Rebecca, Köhler S, Schwanda S, Schmid C
Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001
Wagner U, Krebs D, Bauknecht T, Kreienberg R, Möbus V, Biersack H, Schlebusch H, Renke K, Huober J, Giffels P, Reinartz S, Köhler S, Wallwiener D. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001. Clinical cancer research : an official journal of the American Association for Cancer Research 2001; 7:1154-62.
01.05.2001Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See The biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin. Cancer Res., 7:1112-1115, 2001
01.05.2001Clinical cancer research : an official journal of the American Association for Cancer Research 2001; 7:1154-62
Wagner U, Krebs D, Bauknecht T, Kreienberg R, Möbus V, Biersack H J, Schlebusch H, Renke K, Huober Jens, Giffels P, Reinartz S, Köhler S, Wallwiener D